Lexicon Pharmaceuticals: Q2 Earnings Insights

 

Shares of Lexicon Pharmaceuticals LXRX were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share were up 80.00% over the past year to ($0.13), which beat the estimate of ($0.16).

Revenue of $234,000 decreased by 97.45% year over year, which beat the estimate of $10,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Jul 30, 2021

Time: 08:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/897/42157

Technicals

Company's 52-week high was at $9.65

Company's 52-week low was at $1.03

Price action over last quarter: down 21.83%

Company Description

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!